Managing Non-alcoholic fatty liver disease risk factors in General Practice - 12 April 2022
Novel Therapeutic Strategies to Improve Nonalcoholic Steatohepatitis Outcomes
Non-Alcoholic Fatty Liver Disease and its Link to Chronic Illnesses, Unraveling the Hidden Epidemic.
Noninvasive Assessment of NAFLD/NASH
The Nexus of NASH and Type 2 Diabetes Mellitus
Non-Alcoholic Fatty Liver Disease (NAFLD) and HIV Infection
The Fatty Liver: pathology of NASH with an emphasis on fibrosis - Dr. Saxena (IU) #LIVERPATH
Dr J Bernadetta Moore - Prevention and treatment of non-alcoholic fatty liver disease.
9-7-2023 - MASLD (Formerly Known As NAFLD): Clinical Update and Insights From Human Disease Modeling
Webinar: EASL Update - FibroScan Applications in NAFLD-NASH
S3-E53.1 - The Gut Microbiome and Complexities of NAFLD
Luigi Boccuto, MD Alcoholic Liver Disease (ALD) - Have a Glass of Good Genes
A Practical Approach to the Liver Allograft Biopsy, Dr Parmjeet Randhwa, Prof pathology, SGPGIMS
A Silent Threat :10 Signs That Could Indicate Fatty Liver Disease
Leveraging Clinical Pharmacology to Optimize Drug Development for NASH & Cholestatic Liver Diseases2
PBC Special: PBC, NAFLD and NASH | Dr George Mells and Dr Tessa Cacciottolo | 10 June 2021
Use of Biomarkers for Diagnosing and Assessing Treatment Response in Noncirrhotic NASH Trials-D1-AM
S2-E51 - Precision medicine, Fibrosis, Liver Function and the Future: a Discussion With Scott Fried
PSH 2021 NAFLD 20210922 192314 Meeting Recording
Pathophysiology of Metabolic Syndrome with Emphasis on Nutrition in Causation and Treatment of NASH
